News >

Expert Shares Insight on Immunotherapy, Emerging Strategies in Prostate Cancer

Angelica Welch
Published: Tuesday, Jan 30, 2018

David R. Wise, MD, PhD

David R. Wise, MD, PhDD
2018 may be the year that checkpoint inhibition breaks through in the treatment landscape of prostate cancer, according to David R. Wise, MD, PhD.

on Genitourinary Cancers, Wise, an assistant professor at NYU Langone’s Perlmutter Cancer Center, discussed the promise for immunotherapy and other emerging approaches in the field of prostate cancer.

OncLive: Can you please provide an overview of your presentation?

Wise: I gave an overview of some of the newer approaches for prostate cancer treatment. I covered some of the recent advancements in novel androgen receptor (AR)-directed therapies for use in advanced prostate cancer, with the theme of "earlier is better.” Using our more effective and very well-tolerated therapeutics in patients who present with newly diagnosed metastatic non–castration-resistant prostate cancer has dramatically improved outcomes, and our patients are already benefitting from them. We took more of a granular look at those studies and analyzed some of the limitations, but also some of the nice results and how to apply them in the current clinical setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x